Monoclonal RPE Cell Lines Using Open Chromatin Insertion Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Generating a suitable monoclonal cell line for stable, high-level expression of therapeutic substances is time-consuming and expensive due to the unpredictability of genomic locations allowing long-term expression without transgene silencing and minimal negative effects on cell functionality.
Innovation Solution
Identifying specific open chromatin regions in the human retinal pigment epithelial (RPE) cell line genome for exogenous transcription unit insertion, using defined nucleotide positions on Chromosomes 2, 5, and 12, to achieve stable, high expression of polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If random genomic locations are used for transgene insertion, then cell diversity is maintained, but expression stability and predictability deteriorate
Solution Approach 1:
The patent applies local quality by identifying specific open chromatin regions (OCRs) within the genome that possess favorable local characteristics for stable transgene expression. Rather than treating the entire genome uniformly, the invention targets specific genomic locations (OCRs) that have been pre-characterized to support high-level, stable expression, thereby resolving the contradiction between expression stability and genomic complexity.
2Stability of the object's composition
If multiple screening steps are performed to identify suitable monoclonal cell lines, then expression stability is improved, but time and cost increase
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing open chromatin regions that are conducive to stable transgene expression. By performing this genomic analysis in advance and establishing a library of suitable OCRs, the invention eliminates the need for time-consuming screening of multiple monoclonal cell lines, as insertion into these pre-validated regions directly yields stable expressors.
Solution Approach 2:
The patent applies skipping by bypassing the traditional multi-step screening process for identifying stable cell lines. By directly targeting proven open chromatin regions for transgene insertion, the invention rushes through the lengthy screening phase and achieves stable expression much more quickly, thereby reducing the time and resources required for cell line development.
3Ease of manufacture
If traditional random insertion methods are used, then ease of genetic modification is maintained, but expression level predictability deteriorates
Solution Approach 1:
The patent applies parameter changes by shifting from random genomic insertion to targeted insertion at specific open chromatin regions. This change in the insertion parameter (from random to targeted) maintains the ease of genetic modification while dramatically improving the predictability and precision of expression levels, as the targeted OCRs have been pre-validated to support high-level expression.
Data Source
AI summary
Described herein are genetically modified cells derived from a human cell and which contain at least one exogenous transcription unit inserted into at least one of four open chromatin regions (OCRs) located on Chromosomes 2, 5, 8 and 12, as well as compositions, pharmaceutical preparations, and implantable devices comprising the genetically modified cells, and methods of using the same for preventing or treating a disease, disorder, or condition.